Role of free radicals in the pathogenesis of cystic fibrosis
In recent years directly examined this balance in cystic fibrosis. Langley et al'3 used the TRAP (total radical trapping antioxidant parameter) assay to investigate the ability of plasma from patients with cystic fibrosis to act as a buffer against lipid peroxidation initiated by an extracellular peroxyl radical generator 2,2'-azobis(2-amidinopropane) HC1 (ABAP). They found that the buffering ability was significantly decreased when compared with plasma from age matched controls. They also measured the individual plasma antioxidants that contributed to the TRAP value and found that, as a consequence of modern methods of managing cystic fibrosis, plasma antioxidant defences were normal or even increased in these patients. In particular, plasma concentrations of vitamin C were found to be raised in a subgroup of patients with cystic fibrosis. At normal physiological concentrations vitamin C acts as a potent antioxidant, but at higher concentrations it has been postulated to act as a pro-oxidant in the presence of ferric iron"4 by reducing it to ferrous iron which can then catalyse the formation of 'OH from H202. It has been shown in a control population that elevation of plasma concentrations of vitamin C (by oral loading) to levels equivalent to those seen in this subgroup of cystic fibrosis patients produces a similar reduction in TRAP.'5 It is therefore feasible that the reduction in TRAP activity found in these patients resulted from the pro-oxidant activity of vitamin C. In their discussion Langley et al '3 concluded that a subpopulation of children with cystic fibrosis had a reduced ability to withstand oxidative stress and therefore should, in the event of increased free radical flux, exhibit elevated indices of oxidative damage. 23 Following stimulation, neutrophils and macrophages assemble a multienzyme complex that reduces molecular oxygen (02) to produce several highly reactive and very toxic species including superoxide (02'-), hydroxyl radicals ('OH), singlet oxygen (102), and hydrogen peroxide (H202) (table 3).24 In the context of defence, these reactive oxygen species are considered a potent mechanism for killing organisms. At sites of inflammation oxygen radicals and proteolytic enzymes may act extracellularly and damage the host tissues.25 However, the relative importance of oxygen radicals as contributors to lung damage in cystic fibrosis is still unknown.
The degree of activation of circulating plasma neutrophils in patients with cystic fibrosis has been examined, for example, by Graft et al26 who compared the chemiluminescence response to zymosan of neutrophils from control subjects and adolescents with cystic fibrosis and found no difference in the peak response. However, the peak response was reached more rapidly in the patients with cystic fibrosis and the authors concluded that the neutrophils were in a "primed" state since they found a correlation between clinical scores and the speed of onset of the response. Roberts and Stiehm27 established that both neutrophils and monocytes from patients with cystic fibrosis were more active than those from controls for a range of test stimuli.
Evidence that a hyperresponse to infection by the immune system in patients with cystic fibrosis may not be beneficial is also provided by studies of immunoglobulin levels. High serum concentrations of immunoglobulin have paradoxically been associated with an unfavourable outcome in cystic fibrosis, and patients with hypogammaglobulinaemia and cystic fibrosis have been found to have a better prognosis than those with normal or increased y-globulin levels.28 Patients with higher titres of serum antibodies specific to Ps aeruginosa have poorer pulmonary function and a decreased survival rate than those with lower titres.29
Although the immune response to pulmonary infection in patients with cystic fibrosis may provide one source of oxidative species, it is known that Ps aeruginosa can itself produce toxic reactive oxygen species. Britigan et alP0 have shown that two secretory products of Ps aeruginosapyochelin and pyocyanin -can act in a synergistic fashion to damage pulmonary artery endothelial cells in vitro. The mechanism appears to involve the endothelial cell mediated redox cycling of pyocyanin leading to the production of 02 -/H202 which is then converted to the more cytotoxic *OH radical through the catalytic activity of ferripyochelin.3' Additionally, H0iby and colleagues32 have shown that sputum from patients with cystic fibrosis with chronic Ps aeruginosa infection contains factors of a bacterial endotoxin and immune complex nature which are able to attract neutrophils to the lungs and to prime for enhanced release of oxygen radicals as suggested previously by Roberts succinate cytochrome c reductase, were significantly elevated in cystic fibrosis. The implication of these findings is that various components of the electron transport chain can "leak" electrons and act as sources of partially reduced oxygen intermediates.35 Increased oxygen consumption by cells from patients with cystic fibrosis, and the consequent increased activity of the electron transport chain, will therefore be potentially damaging through an increase in the intracellular generation of oxygen free radicals. We recently obtained evidence to support this hypothesis in a study in which significantly elevated (p < 0-01) concentrations of 8-hydroxydeoxyguanosine were found in the urine of cystic fibrosis patients compared with age matched controls (R K Brown and F J Kelly, unpublished observations). Since the presence of this marker is now accepted as a reliable index of oxidative damage to DNA, these findings substantiate data that indicate that intracellular oxidative metabolism is increased in tissues of patients with cystic fibrosis.
A further source of increased intracellular free radical generation in cystic fibrosis patients may be heightened P450 activity (table 3) . A study of the metabolism of theophylline 6 in patients with cystic fibrosis concluded that heightened free radical production could be a reflection of enhanced P450 activity since oxygen free radicals play an important part in oxidative detoxification reactions. These reports received further support from a study by Matkovics et aP1 showing that the activities of intracellular antioxidant enzymes in plasma erythrocytes were elevated above control values, possibly due to "priming" by increased exposure to reactive oxygen species.
Evidence for oxidative damage in cystic fibrosis Although the evidence for increased oxidative stress in cystic fibrosis is strong, the consequences of such stress have received relatively little attention from direct studies to determine the presence of specific markers of oxidative injury. This is partly because of technical difficulties since the only definitive way to demonstrate excessive free radical activity in vivo is by electron spin resonance study of tissues; unfortunately this cannot be used at present in clinical practice because of the nature of the spin traps. Instead investigations have to rely on the measurement of established clinical markers of free radical activity in biological fluids, most of which reflect free radical attack on polyunsaturated fatty acids in cell membranes. A classical route of free radical attack is through lipid peroxidation generating hydroperoxides, endoperoxides, long-lived aldehydes (notably 4-hydroxynonenal), and the end products malondialdehyde, ethane, and pentane. There are also markers of oxidative damage to proteins and DNA, namely protein carbonyls and 8-hydroxydeoxyguanosine respectively.
In 1989, before the isolation of the cystic fibrosis gene, Salh et al6 suggested that aberrant free radical activity might underlie cellular dysfunction in the disease. Their evidence was based on measurement of the molar ratio of octadeca-9,11-dienoic acid to linoleic acid as an index of free radical attack on polyunsaturated fatty acids. They measured this marker in nasal epithelial cells and in serum and found it to be significantly elevated compared with values in appropriate controls. Measurements of serum levels of malondialdehyde were also made but were found not to be significantly increased in patients with cystic fibrosis. A similar observation on malondialdehyde had previously been made by Matkovics et aP8; however, both investigations used thiobarbituric acid reactive substances (TBARS) as the marker of lipid peroxidation, and it is now recognised that these should not be used as the sole index. 39 Reservations have also been expressed over the suitability of the molar ratio of octadeca-9,1 1-dienoic acid to linoleic acid as a marker, as the former may be produced by bacteria in the gut. 40 In a recent study of cystic fibrosis patients attending an outpatient clinic at Southampton General Hospital4' the levels of two different markers of oxidative damage to lipids (TBARS and free fatty acid hydroperoxides), and of a marker of oxidative protein injury ( Future directions for research and clinical implications There appear to be two major sources of oxygen free radicals in cystic fibrosis: firstly, those produced by an underlying primary defect in intracellular oxygen metabolism, and secondly, those produced by neutrophils in the lung as a consequence of the pulmonary infection associated with the disease. At present it is not known which source, if any, dominates at any one time. It is possible, however, that the primary defect is responsible for a background level of radical production while episodic infectious periods result in heightened free radical activity. In recognising that free radical mediated damage may play a part in the pathogenesis of cystic fibrosis, it is important to address the clinical implication of these findings. For instance, there is evidence of increased oxidative damage to DNA in cystic fibrosis and the number of reports of cancers in patients with cystic fibrosis is rising as their life expectancy increases.447 The relation between the two may be exceedingly important, and may become more so with the advent of gene therapy. It is conceivable that, even if gene therapy should reduce the mortality of cystic fibrosis patients from pulmonary complications, their increased life expectancy may lead to an increase in malignancies due to an as yet unrecognised intracellular oxidative burden.
Patients with cystic fibrosis may benefit from an increased array of antioxidant defences against damage to macromolecules such as DNA, lipids, and proteins, as the evidence to date suggests that damage is occurring in spite of normal plasma antioxidant concentrations. This should prompt a review of what constitutes "adequate" antioxidant levels in the presence of a chronic oxidative burden, and we believe further investigation is warranted.
Until recently investigations along these lines have been extremely difficult, but with the development of transgenic mouse models of cystic fibrosis, tissue is becoming available and intracellular oxidant stress can be studied with greater precision. The mouse model also allows for more intense investigation of the pulmonary involvement of free radicals in the deterioration of lung function by focusing on the role of neutrophils and pulmonary antioxidants, where previously human bronchoalveolar lavage and biopsy samples were rarely available. The advent of genetic therapy for cystic fibrosis should not, however, be seen as a cure for this disabling disease, but as a spur to increased research into its pathology which may prove of great importance. 
